PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - NO0010000045 - Common Stock
61.5 NOK
-0.2 (-0.32%)
We assign a fundamental rating of 5 out of 10 to PHO. PHO was compared to 50 industry peers in the Pharmaceuticals industry. PHO has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PHO has reported negative net income.
PHO had a positive operating cash flow in the past year.
In the past 5 years PHO reported 4 times negative net income.
PHO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
PHO's Return On Assets of -0.78% is on the low side compared to the rest of the industry. PHO is outperformed by 64.00% of its industry peers.
PHO's Return On Equity of -1.11% is on the low side compared to the rest of the industry. PHO is outperformed by 64.00% of its industry peers.
PHO has a Return On Invested Capital of 0.11%. This is in the lower half of the industry: PHO underperforms 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROIC | 0.11% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of PHO (0.17%) is worse than 64.00% of its industry peers.
PHO's Operating Margin has declined in the last couple of years.
PHO's Gross Margin of 93.40% is amongst the best of the industry. PHO outperforms 94.00% of its industry peers.
In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
PHO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
PHO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.13 indicates that PHO is not in any danger for bankruptcy at the moment.
PHO has a better Altman-Z score (6.13) than 88.00% of its industry peers.
There is no outstanding debt for PHO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.13 |
ROIC/WACC0.01
WACC8.45%
2.3 Liquidity
A Current Ratio of 4.78 indicates that PHO has no problem at all paying its short term obligations.
PHO has a better Current ratio (4.78) than 98.00% of its industry peers.
PHO has a Quick Ratio of 4.29. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
PHO has a Quick ratio of 4.29. This is amongst the best in the industry. PHO outperforms 98.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -156.82%.
Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 1.81% in the last year.
PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.29% yearly.
EPS 1Y (TTM)-156.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)1.81%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%9.54%
3.2 Future
The Earnings Per Share is expected to grow by 162.31% on average over the next years. This is a very strong growth
PHO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.98% yearly.
EPS Next Y419.83%
EPS Next 2Y168.93%
EPS Next 3Y162.31%
EPS Next 5YN/A
Revenue Next Year9.66%
Revenue Next 2Y8.95%
Revenue Next 3Y11.23%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 65.30, the valuation of PHO can be described as expensive.
PHO's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. PHO is more expensive than 68.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.66. PHO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 65.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 70.00% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as PHO.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48 | ||
| EV/EBITDA | 47.7 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHO's earnings are expected to grow with 162.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y168.93%
EPS Next 3Y162.31%
5. Dividend
5.1 Amount
PHO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (9/8/2025, 4:19:47 PM)
61.5
-0.2 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.92%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.67B
Analysts80
Price Target81.09 (31.85%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)138.57%
Min EPS beat(2)15.13%
Max EPS beat(2)262.02%
EPS beat(4)3
Avg EPS beat(4)30.25%
Min EPS beat(4)-203.96%
Max EPS beat(4)262.02%
EPS beat(8)5
Avg EPS beat(8)48.5%
EPS beat(12)7
Avg EPS beat(12)20.94%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)3
Avg Revenue beat(8)-3.45%
Revenue beat(12)6
Avg Revenue beat(12)-2.68%
Revenue beat(16)7
Avg Revenue beat(16)-4.3%
PT rev (1m)2.58%
PT rev (3m)2.58%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-59.86%
EPS NY rev (3m)-59.86%
Revenue NQ rev (1m)0.28%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-1.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 65.3 | ||
| P/S | 3.19 | ||
| P/FCF | 48 | ||
| P/OCF | 36.21 | ||
| P/B | 3.48 | ||
| P/tB | 6.72 | ||
| EV/EBITDA | 47.7 |
EPS(TTM)-0.25
EYN/A
EPS(NY)0.94
Fwd EY1.53%
FCF(TTM)1.28
FCFY2.08%
OCF(TTM)1.7
OCFY2.76%
SpS19.28
BVpS17.69
TBVpS9.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROCE | 0.14% | ||
| ROIC | 0.11% | ||
| ROICexc | 0.18% | ||
| ROICexgc | 0.49% | ||
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% | ||
| FCFM | 6.65% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.76% | ||
| Cap/Sales | 2.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 | ||
| Altman-Z | 6.13 |
F-Score4
WACC8.45%
ROIC/WACC0.01
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-156.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y419.83%
EPS Next 2Y168.93%
EPS Next 3Y162.31%
EPS Next 5YN/A
Revenue 1Y (TTM)1.81%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%9.54%
Revenue Next Year9.66%
Revenue Next 2Y8.95%
Revenue Next 3Y11.23%
Revenue Next 5Y14.98%
EBIT growth 1Y-97.81%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year105.28%
EBIT Next 3Y59.66%
EBIT Next 5YN/A
FCF growth 1Y-3.32%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y9.51%
OCF growth 3Y47.56%
OCF growth 5Y30.02%